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Disorganisation and aggregation of proteins containing expanded polyglutamine (polyQ) repeats, or ectopic expression of α-
synuclein, underlie neurodegenerative diseases including Alzheimer’s, Parkinson, Huntington, Creutzfeldt diseases. Small heat-
shock proteins, such as αB-crystallin, act as chaperones to prevent protein aggregation and play a key role in the prevention of such
protein disorganisation diseases. In this study, we have explored the potential for chaperone activity of αB-crystallin to suppress
the formation of protein aggregates. We tested the ability of αB-crystallin to suppress the aggregation of a polyQ protein and α-
synuclein in Drosophila. We found that αB-crystallin suppresses both the compound eye degeneration induced by polyQ and the
α-synuclein-induced rough eye phenotype. Furthermore, by using histochemical staining we have determined that αB-crystallin
inhibits the aggregation of polyQ in vivo. These data provide a clue for the development of therapeutics for neurodegenerative
diseases.
1.Introduction
Expansion of polyglutamine (polyQ) domains causes inher-
ited neurodegenerative diseases, such as Huntingtons, dis-
ease, various types of spinocerebellar ataxia, and spinob-
ulbar muscular atrophy (SBMA) [1, 2]. The formation of
intranuclear inclusions of polyQ-containing proteins in the
brain is one of the pathological features of these diseases.
Inhibition of the aggregation of the expanded polyQ-
containing proteins may thereforeprovide treatmentoptions
for polyQ diseases [3]; however, the relationship between
polyQ aggregation and cellular toxicity is not well under-
stood. It was demonstrated in earlier studies in human cells
that targeted expression of proteins with an expanded polyQ
repeat led to nuclear inclusion formation followed by late-
onsetcelldegeneration.Similarobservationshavebeenmade
inDrosophilasuggestingthatthecellularmechanismsunder-
lying human glutamine-repeat diseases are conserved in
invertebrates [4]. From a therapeutic view point, Drosophila
provides a unique system in which to search for novel genetic
factors that suppress cellular toxicity. Previous studies have
indicated that QBP1 (polyQ binding peptide 1) binds to the
expanded polyQ stretch and inhibits aggregate formation of
the expanded polyQ protein in vitro [5, 6]. Furthermore, Ter
94, the Drosophila homolog of the myeloid leukemia factor
1, and heat-shock-transcription-factor-1 (HSF1-) activating
compounds are also reported to have a dominant role in
suppressing polyQ aggregation [7–9].
Alpha-crystallins (α-crystallins) are major protein com-
ponents of the vertebrate eye lens. The α-crystallins and
especially αB-crystallin are also found outside the lens,
and show a wide tissue distribution [10]. The αB-crystallin
protein is found to be overexpressed in many neurological
diseases, and mutations in αA- or αB-crystallin can cause
cataracts and myopathy [11]. The αB-crystallin protein is a
member of the small heat shock protein family, and it has
a chaperone-like function [12–15]. Therefore, αB-crystallin
can bind to the unfolded proteins and inhibit nonspeciﬁc
aggregation [10]. Consistent with this it has been shown to
prevent the ﬁbrillar aggregation of proteins implicated in2 Journal of Biomedicine and Biotechnology
human diseases and limit the onset of misfolding diseases
[16–18]. Furthermore, accumulation of αB-crystallin is an
important mechanism for the prevention of cellular damage
associated with heat shock and oxidative stress conditions in
the trabecular meshwork [19, 20].
α-synuclein is a presynaptic protein whose major role
in neurodegeneration was recognized in Parkinson disease
where a mutation in the α-synuclein gene was associated
with autosomal dominant inheritance of the disease [21]. It
is reported that αB-crystallin interacts with α-synuclein to
protect against amyloid aggregation and limit the onset of
misfolding diseases in vitro [16].
In the present study, we investigate the ability of the
molecular chaperone, αB-crystallin, to inhibit the aggre-
gation of protein induced by ectopic expression of polyQ
and α-synuclein in ﬂy model. Our results indicate that αB-
crystallin suppresses the neurodegenerative eﬀects induced
by overexpression of polyQ as well as α-synuclein.
2.MaterialandMethods
2.1. Fly Strains. Fly strains were maintained at 25◦Co n
standard food. The transgenic ﬂy line carrying GMR-GAL4
on X chromosome was described earlier [22] as was the
transgenic ﬂy line carrying gmr-Q92 [4, 7]. The UAS-LacZ
ﬂies used in this study were obtained from Bloomington
Drosophila stock center. Wild-type ﬂies: W; UAS-α syn; +,
was obtained from. Feany and Bender [23].
2.2. Plasmid Construction and Establishment of Transgenic
Flies. To construct the plasmid pUAS-αB-crystallin-HA,
the full coding sequence of human αB-crystallin cDNA
(accession number S45630) corresponding to amino acids
(aa) 1 to aa175 was ampliﬁed by PCR with primers carrying
BglII site and XhoI site (aB-crystallin-BglII: 5 -gca gat ctg aca
tcg cca tcc acc acc, aB-crystallin-XhoI: 5 -c g ct c ga g ct a tt t ct t g
ggg gct gc). The PCR products were digested with BglII and
XhoI and inserted into the plasmid pUAST-HA (Lablife).
The P element-mediated germ line transformation with
pUAS-αB-crystallin-HA was carried out as describe earlier
[24], and F1 transformants were selected on the basis of
white-eye color rescue [25]. The established transgenic ﬂy
lines and their chromosome linkages are listed in Table 1.
2.3. Western Immunoblot Analysis. Proteins were extracted
from eye imaginal discs of third-instar larvae, applied to
a SDS-polyacrylamide gel containing 12% acrylamide and
transferred to polyvinylidene diﬂuoride membranes (Bio-
Rad) in transfer buﬀer (50mM borate-NaOH, pH 9.0, and
20% ethanol) by using iBlot system (Invitrogen). The blotted
membranes were incubated with monoclonal antibodies to
HA (HA124, Invitrogen) at 1:400 dilution or anti-αtubulin
IgG (Sigma) at 1:2.000 for 16h at 4◦C. The bound anti-
bodies were detected with peroxidase-conjugated goat anti-
mouse IgG and the ECL system (GE healthcare) according
to the manufacturer’s recommendations. The images were
analyzed with a Lumivision ProHSII image analyzer (Aisin
Seiki, Aichi, Japan).
Table 1:Transgenicﬂylinesestablishedinthisstudyandtheirchro-
mosome linkages.
P-element plasmid Strains Chromosome linkages
UAS-αB-crystallin-HA
27 II
8I I
3 III
11 III
12 III
2.4. Scanning Electron Microscopy. Adult ﬂies were anes-
thetized, mounted on stages, and observed under a VE-7800
scanning electron microscope (Keyence Inc.) in the high
vacuum mode. In every experiment, the eye phenotype of at
leastﬁveadultﬂiesofeachlinewassimultaneouslyexamined
by scanning electron microscopy, and these experiments
were repeated 3 times. In the experiments, no signiﬁcant
variation in eye phenotype among the ﬁve individuals was
observed.
2.5. Immunohistochemistry. Third instar larvae were dis-
sected in PBS, and tissues were ﬁxed in 3% paraformalde-
hyde/PBS for 30min at 25◦C. After washing with PBS/0.3%
TritonX-100 (PBS-T), the samples were blocked with PBS-
T containing 10% normal goat serum for 20min at 25◦C
and incubated with an anti-HA (Invitrogen), anti-FLAG
monoclonal antibody (Sigma), or anti-β-galactosidase mon-
oclonal antibody (Developmental Studies Hybridoma Bank,
DSHB) at a 1:200 dilution at 4◦C for 16h. After extensive
washing with PBS-T, the tissues were incubated with an
anti-mouse IgG conjugated with Alexa 594 or Alexa 488
(Molecular Probes) at a 1:400 dilution each at 37◦Cf o r
1h. After extensive washing with PBS-T and PBS, samples
were mounted in Fluor Guard Antifade Reagent (Bio-Rad)
for microscopic observation under a ﬂuorescence BX-40
microscope(Olympus,Tokyo,Japan)equippedwithacooled
CCD camera (ORCA-ER; Hamamatsu Photonics K. K.,
Shizuoka, Japan).
3. Results and Discussion
3.1. Ectopic Expression of αB-Crystallin Results in Abnormal
Eye Morphology. We ﬁrst established lines of transgenic ﬂies
carrying the uas-human-αB-crystallin.I no r d e rt oc o n ﬁ r m
that human-αB-crystallin is functional in Drosophila,w e
used the gmr-gal4 driver strain to provide ectopic expression
of αB-crystallin-HA from the morphogenetic furrow to the
posterior end of the Drosophila eye imaginal disc [26].
By inspection with the scanning electron microscope, the
compound eyes of adult ﬂies carrying the gmr-gal4 alone
showed normal eye morphology (Figures 1(a) and 1(b)),
while those of ﬂies carrying both the gmr-gal4 and the uas-
αB-crystallin exhibited a rough-eye phenotype (Figures 1(d)
and 1(e)).
To further conﬁrm the expression of αB-crystallin carry-
ing an HA tag in its C-terminal end in eye imaginal discs, weJournal of Biomedicine and Biotechnology 3
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Figure 1: Scanning electron micrographs of adult compound eyes. (a, b) gmr-gal4;+ ;+ .( d ,e )gmr-gal4; uas-αB-crystallin-HA; +. (c, f)
Immunostaining of the eye imaginal discs with anti-HA antibody. The eye disc from gmr-gal4;+; + ﬂies (c) and gmr-gal4; uas-αB-crystallin-
HA; + ﬂies (f). The insets indicate Nomarski images. (g) The anti-HA antibody speciﬁcally recognized αB-crystallin-HA in the Western Blot
of the eye imaginal discs of gmr-gal4; uas-αB-crystallin-HA; + ﬂies.
carried out immunostaining of eye imaginal discs from third
instarlarvaeusinganti-HAantibody.Onlygmr-gal4;uas-αB-
crystallin ﬂies showed ectopic αB-crystallin-HA signals from
the morphogenetic furrow to the posterior end of eye discs
(Figure 1(f)). In contrast, the gmr-gal4 line that was used
as the negative control showed no signal (Figure 1(c)). The
expression of αB-crystallin-HA was further conﬁrmed by the
Western immunoblot analysis of eye imaginal disc extracts
with anti-HA antibody, detecting a single αB-crystallin-HA
band at around 20kDa (Figure 1(g)).
3.2. Expression of αB-Crystallin Suppresses the Compound Eye
Degeneration Induced by PolyQ. To examine the eﬀect of αB-
crystallin protein on polyQ-induced neurodegeneration in
Drosophila, we crossed gmr-Q92 ﬂy lines expressing a Q92
peptide in the eye discs under the direct control of the gmr
promoter [5, 7], and gmr-gal4 > uas-αB-crystallin-HA (uas-
αB-HA)ﬂ i e si nw h i c hαB-crystallin-HA expression is driven
by gmr-gal4.
Expression of the FLAG-tagged 92-glutamine peptides
induced compound eye degeneration such as rough eye
and loss of red eye pigment (loss-of-pigment phenotype)
as described (Figures 2(a) and 2(d)) [5, 7] and the eye
phenotype, especially the loss-of-pigment phenotype, was
eﬀectively rescued by coexpression of αB-crystallin-HA
(Figures 2(c) and 2(f)). In contrast, expression of the control
lacZ protein did not aﬀect the polyQ-induced phenotype
(Figures 2(b) and 2(e)).
3.3. Expression of αB-Crystallin Suppresses PolyQ Aggregate
Formation in the Eye Imaginal Discs. In order to investigate
the ability of αB-crystallin to inhibit polyQ aggregation in
vivo, we examined polyQ aggregate formation in the eye
imaginal discs of third instar larvae in the gmr-Q92 ﬂy
lines with and without expression the αB-crystallin-HA.
PolyQ forms inclusion bodies in the region posterior to the
morphogenetic furrow in eye discs of the gmr-Q92 ﬂies and
many of these aggregate formations could be detected by
immunostaining with anti-FLAG antibody (Figures 3(A1)
and 3(C1)).
Expression of αB-crystallin-HA completely suppressed
formation of the polyQ aggregates in the line exhibiting
am i l de y ep h e n o t y p e( gmr-Q92) (Figure 3(B1)) and dra-
matically suppressed it in the line exhibiting a severe eye
phenotype (2xgmr-Q92) (Figure 3(D1)), while expression of
control lacZ protein exerted no suppressing eﬀect (Figures
3(A1) and 3(C1)). These results suggest correlation between
formation of the polyQ aggregates and neurodegeneration.4 Journal of Biomedicine and Biotechnology
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Figure 2: Suppression of compound eye degeneration by coexpression of αB-crystallin in theQ92-expressing ﬂies. Light microscopic images
of the adult compound eyes of the polyQ lines expressing only one Q92 peptide (a) or 2xQ92 peptide (d) under control of the gmr promoter.
(c, f) Transgenic ﬂies coexpressing Q92 peptides and αB-crystallin (gmr-gal4; gmr-Q92/+;u a s - αB-crystallin-HA). (b, e) Transgenic ﬂies
coexpressing Q92 peptides and control LacZ protein (gmr-gal4; gmr-Q92/+; uas-LacZ). (g) Transgenic ﬂies expressing αB-crystallin alone
(gmr-gal4; uas-αB-crystallin-HA). (h) Transgenic ﬂies expressing lacZ alone (gmr-gal4; uas-LacZ). Magniﬁcation x 90.
3.4. Expression of αB-Crystallin Suppresses the Human α-Sy-
nuclein Induced Rrough-Eye Phenotype. Ap r e v i o u sin vitro
study indicated that αB-crystallin was very eﬀective in sup-
pressing ﬁbrillization of both α-synuclein wild-type and
A30P α-synuclein mutant [15]. Therefore, in this study, to
evaluate ability of αB-crystallin to suppress the rough-eye
phenotype induced by ectopic expression of α-synuclein,
we performed coexpression of αB-crystallin and α-synuclein
in ﬂy eyes and compared the results with those of control
ﬂies coexpressing lacZ and α-synuclein. As noted previously,
overexpression of wild-type α-synuclein induced rough eye
phenotype(Figures4(g)and4(h)).Therougheyephenotype
was signiﬁcantly suppressed by coexpressing αB-crystallin
(Figures 4(a) and 4(b)), while no eﬀect on the rough eye
was observed by coexpressing control lacZ (Figures 4(c)
and 4(d)). These results indicate that αB-crystallin protein
eﬀectively suppresses the events induced by overexpression
of α-synuclein.
In this study, we investigated a role of αB-crystallin on
polyQ aggregation in a Drosophila model to gain insight
into pathways which could be useful in the treatment of
neurodegenerative diseases. We used immunohistochemical
methods to show that the GMR-GAL4/UAS-αB-crystallin
ﬂies expressed an abundant αB-crystallin protein in the
region from the morphogenetic furrow to the posterior end
of eye discs. Consequently, ﬂies exhibit rough-eye phenotype
in adults. These results indicate that the human αB-crystallin
protein is functional in ﬂies.
Previous studies showed that αB-crystallin can act as a
molecular chaperone to prevent ﬁbril formation and aggre-
gation of α-synuclein, β2-microglobulin, and κ-casein in
vitro [10, 12, 15–17, 27–29]. Moreover, chaperone activity
sites of αB-crystallin were identiﬁed in the sequences from
residuesaa73-aa85 and aa101-aa110 [30–32],suggestingthat
expression of full length or a part of chaperone sequences
of this protein is capable of suppressing polyglutamine-
induced protein aggregation. In the present study, we found
that the full-length αB-crystallin could inhibit aggregation
of the 92-polyQ peptide in vivo. The results support the
hypothesis that interactive domains in αB-crystallin play a
role in prevention of protein aggregation. In contrast, the
recent study shows that αB-crystallin does not inhibit or
modify the ﬁbrillar aggregation of SpAcQ52 in vitro [33].
Because glutamine is a hydrophilic amino acid, the surface
hydrophobicity of polyQ may not be changed as aggregation
progresses. Furthermore, the polyQ region is thought to be
in a condensed disordered state in the native conditions [34].
Therefore, the physiochemical properties of the polyQ tractJournal of Biomedicine and Biotechnology 5
Figure 3: Suppression of Q92 aggregate formation by expression of αB-crystallin in the imaginal discs of the Q92 ﬂies. The eye discs were
immunostained with anti-FLAG antibody to detect Q92 tagged with FLAG (green) and anti-HA or anti-LacZ antibodies to detect αB-
crystallin-HA (red) and lacZ, respectively (red). The arrows indicate examples of Q92 aggregates. (A1–A3) gmr-gal4; gmr-Q92/+; uas-
lacZ.( B 1 – B 3 )gmr-gal4; gmr-Q92/+; uas-αB-crystallin-HA.( C 1 – C 3 )gmr-gal4; 2x(gmr-Q92)/+; uas-lacZ.( D 1 – D 3 )gmr-gal4; 2x(gmr-Q92-
FLAG)/+; uas-αB-crystallin-HA.
may lead it to interact with chaperonin diﬀerently in vitro
compared with in vivo. The eﬀectiveness of suppression of
polyQ disorders may also depend on the other factors, such
as the temperature, concentrations of chemical compounds,
or the inhibitor proteins [33, 35, 36]. Here, our data indicate
that inhibition of polyQ-aggregation by αB-crystallin in ﬂies
carrying one copy of the Q92 gene is complete, but ﬂies
carrying two copies of the Q92 gene show only partial
suppression, suggesting the importance of optimization to
determine the eﬀective level of inhibitors for therapies for
polyQ diseases. More interestingly, it is reported that αB-
crystallin is a potent in vitro inhibitor of the ﬁbrillization
of α-synuclein, a protein involved in neurodegenerative
diseases, both wild-type and the two mutant forms (A30P
and A53T) [15, 16]. The data we present here suggests that
this is achieved by the interaction of αB-crystallin and α-
synuclein inhibiting further aggregation.
4. Conclusion
The present study has demonstrated an essential role of αB-
crystallin in suppressing the neurodegeneration induced by
polyQ expansion and ectopic expression of α-synuclein in
vivo and suggest a possible target for the development of6 Journal of Biomedicine and Biotechnology
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Figure 4: Suppression of compound eye degeneration by coexpression of αB-crystallin in the α-synuclein-expressing ﬂies. Light microscope
images of the adult compound eyes. (a, b) Transgenic ﬂies coexpressing α-synuclein and αB-crystallin (gmr-gal4/+;u a s - αB-crystallin-HA/+;
uas-α-synuclein/+). (c, d) Transgenic ﬂies coexpressing α-synuclein and control LacZ protein (gmr-gal4/+; uas-LacZ/+;u a s - α-synuclein/+).
(e, f) Control ﬂies (gmr-gal4/+; +; +). (g, h) Transgenic ﬂies expressing α-synuclein (gmr-gal4/+; uas-α-synuclein/+; +). ( a ,c ,e ,g)
Magniﬁcation x 200. (b, d, f, h) Magniﬁcation x 700.
therapeutics for neurodegenerative diseases. Moreover, the
assay system to suppress neurodegeneration using transgenic
ﬂies described in the present study should be a powerful tool
to evaluate the in vivo eﬀect of peptides carrying potential
chaperone activities, and the αB-crystallin-overexpressing
ﬂies established in this study might provide an invaluable
standard for the evaluation.
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